Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tigris Pharmaceuticals, a developer of targeted cancer treatment therapies, has appointed Pedro Granadillo as the new chairman of the company's board of directors.
Subscribe to our email newsletter
Mr Granadillo served as senior vice president for Eli Lilly and Company until his retirement in 2004 after 34 years of service. Mr Granadillo currently also serves on the boards of directors of Haemonetics of Braintree, Noven Pharmaceuticals, and Nile Therapeutics.
Edmundo Muniz, CEO of Tigris, said: “Pedro’s appointment as chairman of the board of directors will further expand his leadership role within our company and will play a key role in our partnering efforts and corporate strategy. His past experience and proven track record in pharmaceutical drug development will be instrumental as we drive our partnering programs and our clinical programs forward.”